Literature DB >> 19897363

2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly.

Xuejun Zhu1, Guoming Zhao, Xiaoping Zhou, Xiaoqian Xu, Guangqiang Xia, Zhibing Zheng, Lili Wang, Xiaohong Yang, Song Li.   

Abstract

A series of novel 2,4-diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives were designed and synthesized as potent inhibitors of HBV capsid assembly. These compounds arose from efforts to rigidify an earlier series of heteroaryldihydropyrimidines (HAPs), and compounds 12, 13, 20, 24, 30 and 32 showed potent inhibition of HBV capsid assembly, especially 24 with IC(50) value at sub-micromolar range. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19897363     DOI： 10.1016/j.bmcl.2009.10.119

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  12 in total

1.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

2.  Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.

Authors:  Sebastien Boucle; Xiao Lu; Leda Bassit; Tugba Ozturk; Olivia Ollinger Russell; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2017-01-06       Impact factor: 2.823

Review 3.  Treatment of hepatitis B virus: an update.

Authors:  Haley Ward; Lydia Tang; Bhawna Poonia; Shyam Kottilil
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

4.  One-pot synthesis, X-ray crystal structure, and identification of potential molecules against COVID-19 main protease through structure-guided modeling and simulation approach.

Authors:  Youness El Bakri; Malahat Musrat Kurbanova; Sabir Ali Siddique; Sajjad Ahmad; Souraya Goumri-Said
Journal:  Arab J Chem       Date:  2022-09-15       Impact factor: 6.212

5.  Strategies to eliminate HBV infection.

Authors:  Rama Kapoor; Shyam Kottilil
Journal:  Future Virol       Date:  2014       Impact factor: 1.831

6.  Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity.

Authors:  Rebeca Bocanegra; María Nevot; Rosa Doménech; Inmaculada López; Olga Abián; Alicia Rodríguez-Huete; Claudio N Cavasotto; Adrián Velázquez-Campoy; Javier Gómez; Miguel Ángel Martínez; José Luis Neira; Mauricio G Mateu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

7.  Design, synthesis, and characterization of (1-(4-aryl)- 1H-1,2,3-triazol-4-yl)methyl, substituted phenyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates against Mycobacterium tuberculosis.

Authors:  Katharigatta N Venugopala; G B Dharma Rao; Subhrajyoti Bhandary; Melendhran Pillay; Deepak Chopra; Bandar E Aldhubiab; Mahesh Attimarad; Osama Ibrahim Alwassil; Sree Harsha; Koleka Mlisana
Journal:  Drug Des Devel Ther       Date:  2016-08-25       Impact factor: 4.162

8.  An efficient synthesis of enantiopure (R)-heteroarylpyrimidine analogs.

Authors:  Xiu-Yan Yang; Guang-Qiang Xia; Xiao-Kui Wang; Zhi-Bing Zheng; Dong-Mei Zhao; Guo-Ming Zhao; Song Li
Journal:  Molecules       Date:  2013-09-11       Impact factor: 4.411

9.  Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.

Authors:  Dhanabal Kumarasamy; Biswajit Gopal Roy; Joana Rocha-Pereira; Johan Neyts; Satheeshkumar Nanjappan; Subhasis Maity; Musfiqua Mookerjee; Lieve Naesens
Journal:  Bioorg Med Chem Lett       Date:  2016-12-05       Impact factor: 2.823

10.  Synthesis, characterization and biological evaluation of dihydropyrimidine derivatives.

Authors:  Adithya Adhikari; Balakrishna Kalluraya; K V Sujith; Riaz Mahmood
Journal:  Saudi Pharm J       Date:  2011-04-23       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.